# LAM561

Source: https://onco.cc/drugs/lam561/  
OnCo record `lam561` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LAM561 is an experimental small-molecule drug from Laminar Pharmaceuticals in phase 3 trials for glioma & glioblastoma, aimed at MET.

## Summary

LAM561 is a small-molecule drug developed by Laminar Pharmaceuticals. Its target is MET (the sponsor names membrane lipids). The sponsor states: A hydroxylated lipid derivative that targets membrane lipids and induces cytocidal autophagy in cancer models; in Phase 2b/3 testing for newly diagnosed, MGMT-methylated glioblastoma. ClinicalTrials.gov describes the intervention as: Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or r. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT04250922 (LAM561 With RT and TMZ for Adults With Glioblastoma), in glioma & glioblastoma. The largest, NCT04250922, plans to enrol 144 participants (actual) with primary completion was scheduled for 2026-01-15 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: A hydroxylated lipid derivative that targets membrane lipids and induces cytocidal autophagy in cancer models; in Phase 2b/3 testing for newly diagnosed, MGMT-methylated glioblastoma.

## Sources

- ClinicalTrials.gov: trials of LAM561: https://clinicaltrials.gov/search?intr=LAM561
- Sponsor page: https://www.laminarpharma.com

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- targets: [MET](https://onco.cc/targets/met/)
- companies: [Laminar Pharmaceuticals](https://onco.cc/companies/laminar-pharmaceuticals/)
- trials: [LAM561 With RT and TMZ for Adults With Glioblastoma](https://onco.cc/trials/nct04250922/), [Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors](https://onco.cc/trials/nct04299191/)

---
JSON: https://onco.cc/api/v1/entities/lam561.json